EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?

Mohammad Alsaeid, Osamah Abu Hawi, Talat Bessissow iD, Peter L Lakatos iD

Journal of Clinical Medicine · 06.06.2026 · 15 (12) · 4408

DOI: 10.3390/jcm15124408 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.06.2026. Verfasst von Mohammad Alsaeid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada. Die Arbeit nennt 141 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn’s disease can be associated with other immune-mediated inflammatory diseases (IMIDs) and extraintestinal manifestations (EIM) including dermatological manifestations, ophthalmologic manifestations, musculoskeletal manifestations and neurological manifestations. The aim of this narrative review is to discuss the optimal management and treatment strategy of IBD with immune-mediated inflammatory disease and extraintestinal manifestations.

Methods

This review is based on published studies searched in PubMed until 31 December 2025. Our search focused on systemic reviews, review articles, randomized trials, cohort studies, guidelines and case series.

Results

In IBD, the presence of additional immune-mediated inflammatory diseases (IMIDs) should be considered a poor prognostic factor, prompting closer disease monitoring and earlier escalation to or optimization of advanced therapy. Therapeutic management requires careful consideration including a multidisciplinary approach and a selection of the most appropriate treatment option(s) based on the presence, severity of IBD and/or IMIDs and/or EIM. For patients with refractory disease affecting multiple organs, emerging strategies include dual biologic therapies.

Conclusions

The optimal management of IBD with associated IMIDs/EIM should be multidisciplinary in close cooperation among specialists to align treatment goals and management plans.

Schlagwörter

Stichwörter der Autor:innen

CDIBDIMIDUCdermatological manifestationsextraintestinal manifestationsmultidisciplinary approachmusculoskeletal manifestationsneurological manifestationsophthalmologic manifestations

Autor:innen und Institutionen

  • Division of Gastroenterology, McGill University, Montreal, QC H4A 3J1, Canada.
  • Department of Internal Medicine and Oncology, Semmelweis University, 1083 Budapest, Hungary.

ORCID-Profile: Talat Bessissow, Peter L Lakatos

Zitieren

APA

Alsaeid, M., Abu Hawi, O., Bessissow, T., & Lakatos, P. L. (2026). IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?. Journal of Clinical Medicine, 15(12), 4408. https://doi.org/10.3390/jcm15124408

Vancouver

Alsaeid M, Abu Hawi O, Bessissow T, Lakatos PL. IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?. Journal of Clinical Medicine. 2026;15(12):4408. doi:10.3390/jcm15124408

BibTeX
@article{Alsaeid2026,
  author = {Alsaeid, Mohammad and Abu Hawi, Osamah and Bessissow, Talat and Lakatos, Peter L},
  title = {IBD and Immune-Mediated Inflammatory Diseases: What Is the Optimal Management?},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4408},
  doi = {10.3390/jcm15124408}
}
Kostenlos starten →